Showing 4861-4870 of 8786 results for "".
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- UCB’s Bimekizumab Outplays the Competition in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ucbs-bimekizumab-outplays-the-competition-in-two-phase-3-psoriasis-trials/2460764/UCB’s Bimekizumab almost entirely cleared moderate to severe psoriasis in more than 60 percent of the patients who took part in two Phase 3 clinical trials. Given via injection under the skin, Bimekizumab is a monoclonal antibody and the first to block both Interleukin 17A and Int
- Phase 3 Data Show Tolerability, Efficacy for Brickell's Sofpironium Bromide in Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-show-tolerability-efficacy-for-brickells-sofpironium-bromide-in-hyperhidrosis/2460763/Data from the phase 3, open-label, long-term safety study of Brickell Biotech’s sofpironium bromide gel, 5% and 15%, provided clinically meaningful improvement in axillary hyperhidrosis severity as measured by the Hyperhidrosis Disease Severity Measure-
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly select
- Data Show Long-term Safety, Clinical Benefit of Dupilumab in Pediatric ADhttps://practicaldermatology.com/news/data-show-long-term-safety-clinical-benefit-of-dupilumab-in-pediatric-ad/2460757/Dupilumab (Dupixent, Sanofi/Regeneron) is safe and effective for the long-term management of atopic dermatitis in patients as young as six, data from a collection of posters presented at the AAD 2021 VMX show. One study
- Favorable 5-Year Data for Janssen’s Tremfya in PsOhttps://practicaldermatology.com/news/favorable-5-year-data-for-janssens-tremfya-in-pso/2460758/Newly presented phase 3 data show that Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years. Treatment impro
- DermTech Launches DermTech PLAplushttps://practicaldermatology.com/news/dermtech-launches-dermtech-plaplus/2460759/DermTech has launched DermTech PLAplus (TM), its next generation test for the enhanced early detection of melanoma, intended to provide objective and actionable information to guide clinical management decisions for skin lesions suspicious of melanoma.
- C-Jun Protein May Play Role in Psoriasis Developmenthttps://practicaldermatology.com/news/c-jun-protein-may-play-role-in-psoriasis-development/2460753/The "c-Jun" protein may play a major role in the development of psoriasis, but inhibiting this protein may alleviate symptoms, new research suggests. c-Jun belongs to a larger family of transcription factors, DNA-binding factors, known as Activator Protein-1 (AP-1). Previ
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- Qwo Performs Well in Two Phase 3 Studies of Cellulite on the Buttockshttps://practicaldermatology.com/news/qwo-performs-well-in-two-phase-3-studies-of-cellulite-on-the-buttocks/2460747/Endo’s Qwo provides a clinically meaningful improvement in the appearance of moderate to severe cellulite in the buttocks of adult women, when compared to placebo, according to Phase 3 data. "The data, from the largest cellulite studies ever conducted, provides further eviden